关键词: 顺铂, 腹腔化疗, 卵巢早衰, 抗苗勒氏管激素, 动物模型

Abstract: Objective To investigate a method for establishing a rat model of chemotherapy-induced premature ovarian failure (POF) in rats by intraperitoneal injection with different dosages of cisplatin. Method Fourty-eight unfertiled female Wistar rats were randomly divided into 6 groups, with 8 rats in each group. Different doses of cisplatin was injected intraperitoneally at different time points incluing: ① control group (group A) without treatment, ② cisplatin intraperitoneal small dose injection group 1 (group B) (1.5 mg/kg once daily for 5 days), ③ cisplatin intraperitoneal small dose injection group 2 (group C) (2.0 mg/kg once daily for 5 days), ④ cisplatin intraperitoneal small dose injection group 3 (group D) (2.5 mg/kg once daily for 5 days), ⑤ cisplatin intraperitoneal high dose injection group 1 (group E) (4 mg/kg once in a week, after a week, re-injection, on total for twice) and ⑥ cisplatin intraperitoneal high dose injection group 2 (group F) (4 mg/kg once in a week, after a week, re-injection for 6 mg/kg, on total for twice), to establish a rat model of chemotherapy-induced injury POF. The general condition, estrous cycle, body weight changes, serum anti-Müllerian hormone (AMH) levels, ovarian pathological changes, and number of follicles at various levels were observed. Result Compared with the control group (group A): the estrous cycle of the rats in each group was significantly disordered, the body weight and serum AMH levels were significantly decreased (P<0.05), in which, the group E was decreased most obviously. The number of follicles in the ovary of each group was also significantly decreased (P<0.05), but the number of follicles in the groups E and F was more significantly decreased. Conclusion Rats can be injected intraperitoneally with 4 mg/kg cisplatin once a week, at intervals of one week, for two weeks. This model method of chemotherapy-induced POF is more effective, and the method of modeling is simple.

Key words: Cisplatin, Intraperitoneal chemotherapy, Premature ovarian failure, Anti-Mülerian hormone, Animal model